secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001819790-23-000070
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus posts Q2 net loss $31.4M, gets FDA nod for XDEMVY, raises $100M
----------------------------------------------------------------------

- Net loss of $31.4M in Q2 2023 vs $5.7M loss in Q2 2022; no license revenue ($15.3M in prior year).
- Cash and marketable securities $178.2M at June 30, 2023; gross proceeds of $100M from August 2023 equity offering.
- FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis on July 24, 2023; launch expected end of August 2023.
- Completed enrollment of Galatea Phase 2a trial evaluating TP-04 for Rosacea; topline data expected in 1H 2024.
- Recruited 85-person sales force targeting ~15K optometrists/ophthalmologists; deployed by end of August.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/0001819790-23-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/tars-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001819790-23-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer